Adaptimmune Therapeutics Plc (ADAP) — Cash Flow Reinvestment Rate
Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting $1.50 Million (capex $754.55K plus investments $-743.00K) from operating cash flow of $47.39 Million. See Adaptimmune Therapeutics Plc (ADAP) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Adaptimmune Therapeutics Plc Cash Flow Reinvestment Rate (2013–2021)
Historical reinvestment intensity for Adaptimmune Therapeutics Plc across 2 annual periods. For the full cash flow conversion analysis, see ADAP operating cash flow.
Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics Plc (2013–2021)
Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics Plc. See financial agility of Adaptimmune Therapeutics Plc to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 8.70x | $93.36 Million | $10.73 Million | $8.78 Million | ▲ +485.6% |
| 2013 | 1.49x | $55.33 Million | $37.23 Million | $1.45 Million | — |